# A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06716424` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06716424](<https://clinicaltrials.gov/study/NCT06716424>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06716424

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

## Technical summary

Registry record NCT06716424. Allocation not applicable; no masking; primary purpose other. Start 2025-01-06 (actual); primary completion 2026-06-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Phase 4
- Enrolled: 105 participants (enrolled count; ClinicalTrials.gov record NCT06716424, source copy `cardio:ctgov-nct06716424-2026-07-10`, retrieved 2026-10-26)
- Started: 2025-01-06 (actual) (ClinicalTrials.gov record NCT06716424, source copy `cardio:ctgov-nct06716424-2026-07-10`, retrieved 2026-10-26)
- Primary completion: 2026-06-12 (actual) (ClinicalTrials.gov record NCT06716424, source copy `cardio:ctgov-nct06716424-2026-07-10`, retrieved 2026-10-26)
- Completion: 2026-06-12 (actual) (ClinicalTrials.gov record NCT06716424, source copy `cardio:ctgov-nct06716424-2026-07-10`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT06716424, source copy `cardio:ctgov-nct06716424-2026-07-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06716424-2026-07-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes
- Intervention (Drug): iGlarLixi (insulin glargine/lixisenatide)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: dcf439d00050ffcfc3f0e188d104bb67bee3ceff6f7f10d4dc9e03caddb5dc8c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
